Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)
Technology appraisal
Reference number: TA1112
Published:
Tools and resources
Tools and resources to help you put the guidance into practice.